ADARx Pharmaceuticals Raised $446M in Nasdaq IPO

Biotech operators should note how the company leveraged a concurrent private placement to secure $535 million in capital.

Updated on Sept. 29, 2026 in Healthcare

Isometric editorial illustration of a single medical vial containing crystal structures, representing biotech financing. — ADARx Pharmaceuticals raised $446.3 million in a Nasdaq initial public offering, successfully closing a total financing package of over $535 million. AI Illustration. Upload story photo >

Live Poll

Is now a good time for individual investors to buy into early-stage biotech IPOs?

ADARx Pharmaceuticals priced its initial public offering of 26.25 million shares at $17 per share, generating $446.3 million in gross proceeds. The company, which focuses on genetic medicine, began trading on the Nasdaq stock exchange on September 25, 2026.

Why it matters

This financing provides significant liquidity to fund clinical development for the company's core assets, including the ongoing Phase III STOP-HAE trial. It follows a strategic pivot toward institutional partnerships, highlighted by a 2025 licensing agreement with AbbVie.

The IPO generated $446.3 million in gross proceeds, bolstered by an $89 million private stock purchase from AbbVie. This follows a $335 million upfront payment from the same partner in May 2025.

The players

ADARx Pharmaceuticals

A clinical-stage biotechnology company that develops small interfering RNA therapeutics for genetic diseases.

AbbVie

A global research-based biopharmaceutical firm that uses its large scale to invest in early-stage development pipelines.

The details

ADARx priced its shares at the high end of its expected range to finalize the $535.2 million total financing package. The capital structure involves a blend of public equity and strategic investment, a model designed to sustain operations during the development of its onvuzosiran candidate. The company plans to use this runway to reach key milestones, including Phase III topline data expected by the end of 2027.

ADARx Pharmaceuticals was co-founded in 2019.
AbbVie signed a collaboration agreement with ADARx in May 2025.
The STOP-HAE Phase III trial dosed its first patient in October 2025.
ADARx priced its upsized Nasdaq IPO on September 24, 2026.
ADARx shares began trading on Nasdaq on September 25, 2026.

Market Landscape

This financing follows the company's receipt of an FDA Fast Track designation in August 2026, a regulatory status that typically signals potential for accelerated review. The move reflects a broader trend of biotech firms pairing public market debuts with strategic pharmaceutical partnerships to de-risk clinical programs.

Operators in the life sciences sector should track the 2027 Phase III data readout as a bellwether for the clinical viability of siRNA-based therapies. Managers should monitor how the company balances this influx of capital against the 2028 timeline for its anticipated FDA filing.

The takeaway

Large capital raises backed by major pharmaceutical partners offer a blueprint for funding capital-intensive R&D in a volatile IPO market. Executives should monitor the upcoming 2027 clinical data release to gauge the efficacy of the firm's drug development pipeline.